Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant ...

Meanwhile Arcturus, a San Diego biotech working with messenger RNA (mRNA) therapies said it is working with Duke-NUS Medical School (Duke-NUS) to develop a coronavirus vaccine for Singapore.

Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including mRNA, siRNA, replicon RNA, asRNA, DNA, and gene editing therapeutics.

In this article, we are going to take a look at where Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) stands against other worst high-risk high-reward growth stocks to buy. On March 14 ...

Arcturus Therapeutics Holdings Inc. ARCT announced that the FDA has granted a Fast Track designation to its self-amplifying mRNA (sa-mRNA) vaccine candidate, ARCT-2304, for active immunization to ...

Arcturus Therapeutics Holdings has won U.S. Food and Drug Administration fast-track designation for its ARCT-2304 pandemic flu vaccine candidate. Arcturus on Thursday said the designation ...

SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of ...